Microba Life Sciences (ASX:MAP) has announced a series of planned Board changes as part of its renewal process, strengthening governance and commercial capability as the company accelerates its global microbiome business.
The Brisbane-based company has confirmed the appointment of Mr Stéphane Chatonsky as an Independent Non-Executive Director, effective November 20, 2025. At the same time, Non-Executive Directors Mr Richard Bund and Dr Hyungtae Kim will retire from the Board at the company’s Annual General Meeting on 19 November 2025, each after more than six years of service.
Mr Chatonsky brings more than 25 years of experience in venture capital, investment, and corporate strategy across high-growth healthcare, pathology, and technology businesses. His previous roles include senior positions with Lazard, McKinsey & Company, Macquarie Bank, 4Cyte Pathology, Healius and LeapFrog Investments. He currently serves as a Non-Executive Director of Cerulea Clinical Trials and NeoBionica, and as a Senior Advisor to Heidi Health and Vexev.
Microba said Mr Chatonsky’s commercial acumen and governance expertise would further strengthen the Board as it continues to deliver on its global commercialisation strategy and expand its microbiome testing and therapeutics platforms into new markets.
The company also acknowledged the long-standing contributions of Mr Bund and Dr Kim.
vMr Bund joined the Board in 2018 and played a central role in guiding Microba through its early commercialisation phase and successful transition to a listed company in 2022, chairing the Nomination and Remuneration Committee and serving on the Audit and Risk Committee.
Dr Kim, who joined in 2019 as a representative of Macrogen Inc., provided strategic and scientific insight as Microba developed and expanded its core microbiome technology platform.
In a statement, the Board thanked both directors for their leadership, dedication and service over the past seven years, noting their ongoing support for the company’s next phase of growth.
Microba CEO Dr Luke Reid said the changes reflect the company’s continuing evolution into a global microbiome innovator. “We’re entering an exciting period of commercial expansion, and this renewal ensures we have the right mix of experience, governance and strategic insight to deliver on our mission to improve human health through the microbiome,” he said.